U19AI181881
Cooperative Agreement
Overview
Grant Description
Machine learning-enabled design of prototype pathogen vaccines and antibodies - project summary – overall: Machine learning-enabled design of prototype pathogen vaccines and antibodies.
We propose a highly synergistic center focused on developing end-to-end strategies for pandemic preparedness vaccine development for Bunyaviruses and Paramyxoviruses.
Our center brings together five research institutions with complementary and synergistic expertise in computational protein design, structure-based vaccine design, mRNA vaccines, structural biology, viral entry, viral diversity and evolution, animal model development, high biosafety-level containment virology, vaccinology, and vaccine process development and technology transfer.
Our team has real-world experience in vaccine and biologics product development in both academic and industry settings.
Our center comprises five scientific projects supported by three scientific cores, an administrative core, and a data management core.
Our scientific projects include: 1) Development of computational methods for vaccine and biologics design, 2) Fundamental research on viral entry and receptors, 3) Antigen design, 4) Protein nanoparticle vaccine development, and 5) mRNA vaccine development.
We will structure our efforts in two phases: In phase 1 (years 1-3) we will focus on developing vaccines for our prototype pathogens and in phase 2 (years 4-5) we will apply those learnings to two new Bunyaviruses and two new Paramyxoviruses to demonstrate that our computational and experimental approaches generalize across viral families.
Our prototype pathogens are: Lassa virus (LASV; Arenaviruses), Rift Valley fever virus (RVFV; Phenuiviruses), and Hendra virus (HEV; Paramyxoviruses).
We carefully selected our prototypes as we believe they present specific vaccine design challenges which, if we are successful in solving, will facilitate the development of vaccines against related viruses.
Simultaneously, the antigens from viruses in these three families have some similarities that will give rise to synergies in our design approaches.
The structure of our center will allow maximal synergy between our groups in pursuit of its central output: to define generalizable approaches and tools to develop vaccines and biologics for emerging pathogens with pandemic potential.
We propose a highly synergistic center focused on developing end-to-end strategies for pandemic preparedness vaccine development for Bunyaviruses and Paramyxoviruses.
Our center brings together five research institutions with complementary and synergistic expertise in computational protein design, structure-based vaccine design, mRNA vaccines, structural biology, viral entry, viral diversity and evolution, animal model development, high biosafety-level containment virology, vaccinology, and vaccine process development and technology transfer.
Our team has real-world experience in vaccine and biologics product development in both academic and industry settings.
Our center comprises five scientific projects supported by three scientific cores, an administrative core, and a data management core.
Our scientific projects include: 1) Development of computational methods for vaccine and biologics design, 2) Fundamental research on viral entry and receptors, 3) Antigen design, 4) Protein nanoparticle vaccine development, and 5) mRNA vaccine development.
We will structure our efforts in two phases: In phase 1 (years 1-3) we will focus on developing vaccines for our prototype pathogens and in phase 2 (years 4-5) we will apply those learnings to two new Bunyaviruses and two new Paramyxoviruses to demonstrate that our computational and experimental approaches generalize across viral families.
Our prototype pathogens are: Lassa virus (LASV; Arenaviruses), Rift Valley fever virus (RVFV; Phenuiviruses), and Hendra virus (HEV; Paramyxoviruses).
We carefully selected our prototypes as we believe they present specific vaccine design challenges which, if we are successful in solving, will facilitate the development of vaccines against related viruses.
Simultaneously, the antigens from viruses in these three families have some similarities that will give rise to synergies in our design approaches.
The structure of our center will allow maximal synergy between our groups in pursuit of its central output: to define generalizable approaches and tools to develop vaccines and biologics for emerging pathogens with pandemic potential.
Awardee
Funding Goals
NOT APPLICABLE
Grant Program (CFDA)
Awarding / Funding Agency
Place of Performance
Seattle,
Washington
981951016
United States
Geographic Scope
Single Zip Code
University Of Washington was awarded
Prototype Pathogen Vaccines & Antibodies: Machine Learning-Enabled Design
Cooperative Agreement U19AI181881
worth $41,075,241
from the National Institute of Allergy and Infectious Diseases in August 2024 with work to be completed primarily in Seattle Washington United States.
The grant
has a duration of 3 years and
was awarded through assistance program 93.855 Allergy and Infectious Diseases Research.
The Cooperative Agreement was awarded through grant opportunity Research and Development of Vaccines and Monoclonal Antibodies for Pandemic Preparedness (ReVAMPP) Centers for Bunyavirales, Paramyxoviridae and Picornaviridae (U19 Clinical Trial Not Allowed).
Status
(Ongoing)
Last Modified 8/20/24
Period of Performance
8/12/24
Start Date
7/31/27
End Date
Funding Split
$41.1M
Federal Obligation
$0.0
Non-Federal Obligation
$41.1M
Total Obligated
Activity Timeline
Additional Detail
Award ID FAIN
U19AI181881
SAI Number
U19AI181881-2630649576
Award ID URI
SAI UNAVAILABLE
Awardee Classifications
Public/State Controlled Institution Of Higher Education
Awarding Office
75NM00 NIH NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES
Funding Office
75NM00 NIH NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES
Awardee UEI
HD1WMN6945W6
Awardee CAGE
1HEX5
Performance District
WA-07
Senators
Maria Cantwell
Patty Murray
Patty Murray
Modified: 8/20/24